Key Points
- Director Heather Ann Mcsharry sold 3,415 shares on November 20 at an average price of $177.78 for $607,118.70, cutting her holding by 14.31% to 20,449 shares.
- Jazz beat expectations in Q3 with EPS of $8.13 vs. $5.87 expected and revenue of $1.13B, and set FY2025 guidance of 7.65–8.45 EPS.
- Analyst sentiment is largely positive—13 Buy ratings and an average target of $195.67—and the stock trades near its 52-week high (~$181) with a market cap of about $11B.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Heather Ann Mcsharry sold 3,415 shares of the business's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the sale, the director directly owned 20,449 shares of the company's stock, valued at $3,635,423.22. This represents a 14.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Jazz Pharmaceuticals Stock Performance
Shares of NASDAQ JAZZ opened at $180.90 on Tuesday. The business's 50-day simple moving average is $139.97 and its 200-day simple moving average is $123.16. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99. The firm has a market cap of $10.99 billion, a price-to-earnings ratio of -26.88, a P/E/G ratio of 8.49 and a beta of 0.29.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.13 billion during the quarter, compared to analysts' expectations of $1.11 billion. During the same quarter in the prior year, the business earned $6.54 earnings per share. The company's revenue was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.
Institutional Trading of Jazz Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of JAZZ. Dimensional Fund Advisors LP lifted its position in Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after purchasing an additional 298,815 shares during the period. Capital World Investors raised its stake in shares of Jazz Pharmaceuticals by 0.4% in the 3rd quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company's stock valued at $336,731,000 after buying an additional 10,345 shares in the last quarter. LSV Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company's stock worth $271,003,000 after acquiring an additional 87,576 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock valued at $198,159,000 after acquiring an additional 191,637 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company's stock valued at $246,092,000 after acquiring an additional 145,865 shares during the period. 89.14% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently commented on JAZZ. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 18th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the company an "outperform" rating in a research note on Monday, November 17th. The Goldman Sachs Group lifted their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research report on Friday, August 29th. Finally, JPMorgan Chase & Co. reduced their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an "overweight" rating for the company in a research report on Monday, October 27th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $195.67.
Read Our Latest Stock Report on JAZZ
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
